Allogeneic stem cell transplantation for type B insulin resistance

Thomas Ebert, Gerhard Behre, Lorenz Weidhase, Vladan Vucinic, Cornelia Gewert, Robert K Semple, Michael Stumvoll, Anke Tönjes

Research output: Contribution to journalArticlepeer-review

Abstract / Description of output

Type B insulin resistance (TBIR) is a rare, often fulminant form of insulin resistance caused by
autoantibodies against the insulin receptor. Untreated, its mortality is high. Various
immunosuppressive regimens have shown efficacy, but treatment effects are variable and timedelayed, and drug-induced complications may arise. We report a patient with TBIR arising as a complication of Wiskott–Aldrich syndrome. Stable remission of TBIR was achieved through allogeneic peripheral blood stem cell transplantation (PBSCT) over a follow-up period of more than 1.5 years. We thus demonstrate that PBSCT can be considered a treatment option in TBIR where conventional immunosuppressive therapy is ineffective or contraindicated.
Original languageEnglish
JournalFrontiers in Medicine
Publication statusPublished - 29 Aug 2023


Dive into the research topics of 'Allogeneic stem cell transplantation for type B insulin resistance'. Together they form a unique fingerprint.

Cite this